Exome Asset Management »

Vyne Therapeutics shares owned by Exome Asset Management

Quarter-by-quarter ownership of Vyne Therapeutics (VYNE) shares owned by Exome Asset Management from 13F filings

Historical chart of Exome Asset Management investment in Vyne Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Vyne Therapeutics held by Exome Asset Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Vyne Therapeutics by Exome Asset Management

Quarter filed Position value Share count Share price at filing
2024-06-30 $696k 353k 1.97
2024-03-31 $1.3M 415k 3.07
2023-12-31 $275k 118k 2.33

More positions owned by Exome Asset Management

Eli Lilly & Co. (LLY)
Sarepta Therapeutics (SRPT)
Beigene Sponsored Adr (BGNE)
Tg Therapeutics (TGTX)
Cigna Corp (CI)
Corbus Pharmaceuticals Hldgs Com New (CRBP)
Insmed Com Par $.01 (INSM)
Amgen (AMGN)
Travere Therapeutics (TVTX)
Madrigal Pharmaceuticals (MDGL)
Avadel Pharmaceuticals Com Shs (AVDL)
Dex (DXCM)
Autolus Therapeutics Spon Ads (AUTL)
Intuitive Surgical Com New (ISRG)
Dr Reddys Labs Adr (RDY)

View all positions for Exome Asset Management

Top funds holding Vyne Therapeutics

Eventide Asset Management
Cormorant Asset Management
Citadel Advisors
DSC Advisors
Silverarc Capital Management
Palo Alto Investors
Vanguard Group
Exome Asset Management
Parkman Healthcare Partners
AlphaCentric Advisors
Schonfeld Strategic Advisors
Geode Capital Management
Renaissance Technologies
BlackRock
Susquehanna International

View all funds holding Vyne Therapeutics